Worldwide, vaginal candidosis represents a significant health problem in women of childbearing age. The aim of this paper is to evaluate under in vitro conditions resembling the vaginal microenvironment, the antifungal activity of a new propiconazole derivative against 64 strains of yeast species isolated from vulvovaginitis. The tests exhibited low MICs for all strains and this finding may be useful in using of this new azole compound for treatment of mycotic vaginitis.